Exelixis Inc Amortization of Debt Issuance Costs and Discounts
Exelixis Inc (EXEL) reported Amortization of Debt Issuance Costs and Discounts of $0 for the 12-month period ending 2018-12-28, per its 10-K filed 2019-02-22.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2019-02-22
- Exelixis Inc amortization of debt issuance costs and discounts for the quarter ending 2018-12-28 was $0.00.
- Exelixis Inc amortization of debt issuance costs and discounts for the quarter ending 2018-09-28 was $0.00.
- Exelixis Inc amortization of debt issuance costs and discounts for the quarter ending 2018-06-29 was $0.00, a 100.00% decline year-over-year.
- Exelixis Inc amortization of debt issuance costs and discounts for the quarter ending 2018-03-30 was $0.00, a 100.00% decline year-over-year.
- Exelixis Inc amortization of debt issuance costs and discounts for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- Exelixis Inc amortization of debt issuance costs and discounts for fiscal 2017 was $182.00K, a 97.84% decline from fiscal 2016.
- Exelixis Inc amortization of debt issuance costs and discounts for fiscal 2016 was $8.43M.
- Exelixis Inc amortization of debt issuance costs and discounts for fiscal 2016 was $8.43M, a 50.52% decline from fiscal 2016.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 6 month as first filed | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|---|
| 2018-12-28 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $0.00 derived: sum of 2 quarters · filed 2019-02-22 | $0.00 derived: sum of 3 quarters · filed 2019-02-22 | $0.00 10-K · filed 2019-02-22 | |
| 2018-09-28 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $0.00 derived: sum of 2 quarters · filed 2018-11-01 | $0.00 10-Q · filed 2018-11-01 | $0.00 derived: sum of 4 quarters · filed 2019-02-22 | |
| 2018-06-29 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $0.00 10-Q · filed 2018-08-01 | $0.00 derived: sum of 3 quarters · filed 2019-02-22 | $0.00 derived: sum of 4 quarters · filed 2019-02-22 | |
| 2018-03-30 | $0.00 10-Q · filed 2018-05-02 | $0.00 derived: sum of 2 quarters · filed 2019-02-22 | $0.00 derived: sum of 3 quarters · filed 2019-02-22 | ||
| 2017-12-29 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $0.00 derived: sum of 2 quarters · filed 2019-02-22 | $182.00K 10-K · filed 2019-02-22 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $182.00K 10-Q · filed 2017-11-01 | |||
| 2017-09-29 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $93.00K derived: sum of 2 quarters · filed 2018-11-01 | $182.00K 10-Q · filed 2018-11-01 | $319.00K derived: sum of 4 quarters · filed 2018-11-01 | |
| 2017-06-30 | $93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $182.00K 10-Q · filed 2017-08-02 | $319.00K derived: sum of 3 quarters · filed 2018-05-02 | $2.20M derived: sum of 4 quarters · filed 2018-05-02 | |
| 2017-03-31 | $89.00K 10-Q · filed 2017-05-01 | $226.00K derived: sum of 2 quarters · filed 2018-05-02 | $2.11M derived: sum of 3 quarters · filed 2018-05-02 | $5.36M derived: sum of 4 quarters · filed 2018-05-02 | |
| 2016-12-31 | $137.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $2.02M derived: sum of 2 quarters · filed 2017-11-01 | $5.27M derived: sum of 3 quarters · filed 2017-11-01 | $8.43M 10-K · filed 2017-02-27 | |
| 2016-12-30 | $8.43M 10-K · filed 2019-02-22 | ||||
| 2016-09-30 | $1.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $5.13M derived: sum of 2 quarters · filed 2017-11-01 | $8.29M 10-Q · filed 2017-11-01 | $11.06M derived: sum of 4 quarters · filed 2017-11-01 | |
| 2016-06-30 | $3.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $6.41M 10-Q · filed 2017-08-02 | $10.71M 10-Q · filed 2016-08-03 | $9.18M derived: sum of 3 quarters · filed 2017-08-02 | $8.56M derived: sum of 4 quarters · filed 2017-08-02 |
| 2016-03-31 | $3.16M 10-Q · filed 2017-05-01 | $5.93M derived: sum of 2 quarters · filed 2017-05-01 | $5.31M derived: sum of 3 quarters · filed 2017-05-01 | ||
| 2016-01-01 | $17.04M 10-K · filed 2018-02-26 | ||||
| 2015-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $2.15M derived: sum of 2 quarters · filed 2017-02-27 | $17.04M 10-K · filed 2017-02-27 | ||
| 2015-09-30 | -$617.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $14.27M 10-Q · filed 2016-11-03 | |||
| 2015-06-30 | $14.89M 10-Q · filed 2016-08-03 | ||||
| 2014-12-31 | $22.29M 10-K · filed 2017-02-27 | ||||
| 2013-12-31 | $19.72M 10-K · filed 2017-02-27 | ||||
| 2012-12-31 | $12.44M 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |